ストックスクリーナーアプリを入手
9.13
2.73%
0.25
Aurinia Pharmaceuticals Inc (AUPH) 最新ニュース
What analysts say about Aurinia Pharmaceuticals Inc. stockFast-track wealth growth - Autocar Professional
What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a good long term investmentFree AI-Backed Trading Signals - Autocar Professional
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser
How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser
How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest
Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com
Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq
Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail
Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News
Aurinia Pharmaceuticals Inc.(NasdaqGM: AUPH) added to Russell 2000 Defensive Index - MarketScreener
(AUPH) Trading Report - news.stocktradersdaily.com
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - The Joplin Globe
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance
Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
As Edmonton biotech industry booms, Launa Aspeslet steps up to guide further success - Taproot Edmonton
Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
4.47%
0.44%
大文字化:
|
ボリューム (24 時間):